Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Protagonist Therapeutics (PTGX) Long-Term Debt Issuances (2019 - 2023)

Historic Long-Term Debt Issuances for Protagonist Therapeutics (PTGX) over the last 4 years, with Q1 2023 value amounting to $24.3 million.

  • Protagonist Therapeutics' Long-Term Debt Issuances rose 6698.96% to $24.3 million in Q1 2023 from the same period last year, while for Dec 2023 it was $24.3 million, marking a year-over-year increase of 6698.96%. This contributed to the annual value of $24.3 million for FY2023, which is 6698.96% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Long-Term Debt Issuances stood at $24.3 million for Q1 2023, which was up 6698.96% from $14.6 million recorded in Q1 2022.
  • Over the past 5 years, Protagonist Therapeutics' Long-Term Debt Issuances peaked at $24.3 million during Q1 2023, and registered a low of $6.4 million during Q3 2020.
  • In the last 4 years, Protagonist Therapeutics' Long-Term Debt Issuances had a median value of $18.8 million in 2020 and averaged $17.6 million.
  • In the last 5 years, Protagonist Therapeutics' Long-Term Debt Issuances tumbled by 7333.92% in 2020 and then soared by 6698.96% in 2023.
  • Over the past 4 years, Protagonist Therapeutics' Long-Term Debt Issuances (Quarter) stood at $23.9 million in 2019, then decreased by 21.32% to $18.8 million in 2020, then dropped by 22.77% to $14.6 million in 2022, then soared by 66.99% to $24.3 million in 2023.
  • Its Long-Term Debt Issuances stands at $24.3 million for Q1 2023, versus $14.6 million for Q1 2022 and $18.8 million for Q4 2020.